In NSCLC, HER2 protein overexpression was reported in 2% to 30% of cases, gene amplification in 2% to 5%, and mutation in 1% to 4% of cases.15,16 Accumulating evidence suggests that HER2-targeted TKIs hold potential for patients with NSCLC harboring activating HER2 mutations, with reported objective response rates (ORRs) of up to 30% and duration of response (DoR) of up to 6.9 months.17–22 However, anti-HER2 mAb monotherapy had consistently demonstrated limited antitumor activity for HER2-altered NSCLC.23,24. Here, ERBB2 is linked to non-small cell lung carcinoma.